NCT05701995CompletedPhase 4
A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting
Source: ClinicalTrials.gov · Last updated 3 Jun 2026
Brief summary (registry, in English)
The purpose of this study is to evaluate the effect of deucravacitinib on quality of life (QoL) in participants with plaque psoriasis in a community setting.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 180 (actual)
- First submitted
- 16 Jan 2023
- Start date
- 31 Jan 2023
- Primary completion date
- 23 Aug 2024
- Lead sponsor
- Bristol-Myers Squibb
- Diseases
- Psoriasis
- NCT number
- NCT05701995
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 180
- From 31 Jan 2023 to the primary completion date, 23 Aug 2024
- 38 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Non-plaque psoriasis (that is, guttate, pustular, erythrodermic, palmoplantar only involvement or drug-induced psoriasis) at Screening Visit or Day 1
- Other protocol-defined inclusion/exclusion criteria apply.
Other illness
- Target Disease Exceptions:
Who the study is looking for
- Men and women diagnosed with stable plaque psoriasis for 6 months or more. Stable psoriasis is defined as no morphology changes or significant flares of disease activity in the opinion of the investigator.
- Deemed by the investigator to be a candidate for phototherapy or systemic therapy.
- ≥ 3% of Body Surface Area (BSA) involvement at the Screening Visit and Day 1
- Dermatology Life Quality Index (DLQI) score \> 5 at the Screening Visit and Day 1
- Moderate-to-severe plaque psoriasis as defined by static Physician Global Assessment (s-PGA) ≥ 3 at the Screening Visit and Day 1
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (38)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.